Mayo Clinic Researchers ID Potential Gene Marker for Treating Pancreatic Cancer
ROCHESTER, Minn. — Researchers at Mayo Clinic Comprehensive Cancer Center have identified a gene marker that may lead to a more effective, precision treatment for pancreatic ductal adenocarcinoma (PDAC). The researcher’s findings are published in Nature Cancer. “Pancreatic ductal adenocarcinoma is one of t he most lethal cancers,” says the paper’s senior author Zhenkun Lou, Ph.D. Dr. Lou says while Poly-ADP-ribose-polymerase inhibitors (PARPi) are now an FDA-approved option for standard maintenance therapy for patients with metastatic PDAC who harbor pathogenic… (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - September 22, 2022 Category: Research Source Type: news

FDG-PET May Predict Response to Neoadjuvant Therapy in Pancreatic Cancer
THURSDAY, Sept. 15, 2022 -- For patients with borderline resectable/locally advanced (BR/LA) pancreatic ductal adenocarcinoma (PDAC), preoperative fluorodeoxyglucose positron emission tomography (FDG-PET) may predict pathologic response to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 15, 2022 Category: Pharmaceuticals Source Type: news

Epstein-Barr Virus Linked With Gastric Cancer
(MedPage Today) -- A substantial proportion of gastric cancers worldwide was linked with the Epstein-Barr virus (EBV), according to a meta-analysis. In a pooled analysis involving over 68,000 patients with conventional gastric adenocarcinoma in... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - August 12, 2022 Category: Gastroenterology Source Type: news

Radiomics-Based AI Models Can Detect PDAC From Prediagnostic CT
WEDNESDAY, Aug. 10, 2022 -- Radiomics-based machine learning (ML) models can detect pancreatic ductal adenocarcinoma (PDAC) from prediagnostic computed tomography (CT) images, according to a study published online June 30 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 10, 2022 Category: Pharmaceuticals Source Type: news

Neoadjuvant mFOLFIRINOX Studied for Borderline Resectable PDAC
WEDNESDAY, Aug. 3, 2022 -- For patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC), favorable overall survival was observed following treatment with eight cycles of neoadjuvant modified FOLFIRINOX (mFOLFIRINOX), according to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 3, 2022 Category: Pharmaceuticals Source Type: news

Janssen Announces New Data Supporting Safety and Efficacy of RYBREVANT ® and Lazertinib Combination for Patients with Non-Small Cell Lung Cancer and EGFR Mutations
July 26, 2022 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 1b/2 CHRYSALIS-2 study (NCT04077463) cohort evaluating the safety and tolerability of the combination of RYBREVANT® (amivantamab-vmjw) with the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) lazertinib and platinum-based chemotherapy (carboplatin and pemetrexed) in patients with relapsed/refractory non-small cell lung cancer (NSCLC) and EGFR mutations.[1] These findings and additional updates, including data on RYBREVANT® in combination with laze...
Source: Johnson and Johnson - July 26, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Surveillance of High-Risk Group May Downstage Pancreatic Cancer
WEDNESDAY, July 20, 2022 -- Surveillance of high-risk individuals may downstage pancreatic ductal adenocarcinoma (PDAC), according to a study published online June 15 in the Journal of Clinical Oncology. Mohamad Dbouk, M.D., from the Sol Goldman... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 20, 2022 Category: Pharmaceuticals Source Type: news

Chemo-Free Maintenance Combo Promising in Pancreatic Cancer
(MedPage Today) -- Pairing a PARP inhibitor and immune checkpoint inhibitor together may be a viable non-cytotoxic maintenance therapy option for patients with platinum-sensitive pancreatic ductal adenocarcinoma (PDAC), according to findings of... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - July 12, 2022 Category: Hematology Source Type: news

Adding Opdivo in First-Line Shows Promise in HER2+ Esophagogastric Cancer
(MedPage Today) -- A combination of the PD-1 inhibitor nivolumab (Opdivo) plus trastuzumab and chemotherapy (mFOLFOX6) was effective as first-line therapy for patients with HER2 (ERBB2)-positive esophagogastric adenocarcinoma, according to results... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 23, 2022 Category: Hematology Source Type: news

Apollo Cancer Centres launches breast cancer detection test in tie up with Datar Cancer Genetics
The EasyCheck- Breast test developed by Nashik-based molecular diagnostics company Datar Cancer Genetics, has received breakthrough designated status by USFDA and has been approved by the UK and Europe. The test is designed to detect breast adenocarcinoma specific cancer tumor cells in the blood. (Source: The Economic Times)
Source: The Economic Times - June 22, 2022 Category: Consumer Health News Source Type: news

Positive Phase 1 data from mRNA-based individualized neoantigen specific immunotherapy in patients with resected pancreatic cancer
BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability of the mRNA-based individualized neoantigen specific immunotherapy (iNeST) autogene cevumeran (also known as BNT122, RO7198457) in combination with anti-PD-L1 immune checkpoint inhibitor atezolizumab and chemotherapy in patients with resected pancreatic ductal adenocarcinoma (PDAC). (Source: World Pharma News)
Source: World Pharma News - June 9, 2022 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data onglofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leadinghaematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Oncol...
Source: Roche Media News - May 24, 2022 Category: Pharmaceuticals Source Type: news

Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data on glofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leading haematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Onc...
Source: Roche Media News - May 24, 2022 Category: Pharmaceuticals Source Type: news

Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data onglofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leading haematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Onco...
Source: Roche Investor Update - May 24, 2022 Category: Pharmaceuticals Source Type: news

Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data onglofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leadinghaematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Oncol...
Source: Roche Media News - May 24, 2022 Category: Pharmaceuticals Source Type: news